BioCentury
ARTICLE | Company News

Merck announces HIV deals with Chimerix, Yamasa

July 25, 2012 1:52 AM UTC

Merck & Co. Inc. (NYSE:MRK) announced a pair of HIV deals on Tuesday, including one with Chimerix Inc. (Durham, N.C.) for exclusive, worldwide rights to Chimerix's CMX157. The product has completed a Phase I trial in healthy volunteers. Chimerix will receive $17.5 million up front and will be eligible for $151 million in milestones, plus royalties. CMX157 is an oral phospholipid intramembrane microfluidization (PIM)-conjugate chemical modification of tenofovir, a nucleotide analog prodrug reverse transcriptase inhibitor. ...